Cargando…

HTA and Gastric Cancer: Evaluating Alternatives in Third- and Fourth-Line Patients

Metastatic gastric cancer (mGC) represents an economic and societal burden worldwide. The present study has two aims. Firstly, it evaluates the benefits and the added value of the introduction of trifluridine/tipiracil (FTD/TPI) in the Italian clinical practice, defining the comparative efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ferrario, Lucrezia, Asperti, Federica, Aprile, Giuseppe, Giuliani, Jacopo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9915553/ https://www.ncbi.nlm.nih.gov/pubmed/36767474 http://dx.doi.org/10.3390/ijerph20032107

Ejemplares similares

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer
por: Bretoni, Alberto, et al.
Publicado: (2019)

HTA and HIV: The Case of Dual NRTI Backbones in the Italian Setting
por: Garagiola, Elisabetta, et al.
Publicado: (2020)

Leveraging EUnetHTA’s conceptual framework to compare HTA decision drivers in France, Italy, and Germany from a manufacturer’s point of view
por: Giuliani, Giovanni, et al.
Publicado: (2018)

A comparative analysis of a disposable and a reusable pedicle screw instrument kit for lumbar arthrodesis: integrating HTA and MCDA
por: Ottardi, Claudia, et al.
Publicado: (2017)

Expanding HTA – Correcting a Misattribution, Clarifying the Scope of HTA and CEA: Comment on "Ethics in HTA: Examining the ‘Need for Expansion’"
por: Culyer, Anthony J.
Publicado: (2019)

Navigating HTA implementation: a review of Indonesia’s revised HTA guideline
por: Chavarina, Kinanti Khansa, et al.
Publicado: (2023)

Effect of third- and fourth-line systemic therapies for metastatic renal cell carcinoma
por: Naito, Sei, et al.
Publicado: (2019)

Oncologic Outcomes in Metastatic Colorectal Cancer with Regorafenib with FOLFIRI as a Third- or Fourth-Line Setting()()()
por: Ma, Cheng-Jen, et al.
Publicado: (2018)

Suture-Mediated Patent Foramen Ovale Closure Using the NobleStitch EL: Results from a Hospital-Based HTA
por: Gaetti, Giovanni, et al.
Publicado: (2022)

GMS-HTA: Information out of the world of HTA - up-to-date, comprehensive and valid
por: Rüther, Alric
Publicado: (2005)

HTA Training for Healthcare Professionals: International Overview of Initiatives Provided by HTA Agencies and Organizations
por: Hoxhaj, Ilda, et al.
Publicado: (2022)

Evaluating facts and facting evaluations: On the fact‐value relationship in HTA
por: Hofmann, Bjørn, et al.
Publicado: (2018)

Living HTA: Automating Health Economic Evaluation with R
por: Smith, Robert A., et al.
Publicado: (2022)

The Impact of Brexit on Pharmaceuticals and HTA
por: Lorgelly, Paula K
Publicado: (2018)

Towards a more transparent HTA process in Poland: new Polish HTA methodological guidelines
por: Lach, Krzysztof, et al.
Publicado: (2017)

HTA and National Immunisation Program: an overview of competent bodies and of the impact of HTA on the decision-making process
por: Ricciardi, W
Publicado: (2022)

Korobov polynomials of the third kind and of the fourth kind
por: Kim, Taekyun, et al.
Publicado: (2015)

The role of INTERCheckWEB digital innovation in supporting polytherapy management
por: Foglia, Emanuela, et al.
Publicado: (2023)

HTA26 Health Technology Assessment (HTA) Methods for Monoclonal Antibodies for Treatment and Prevention of COVID-19
por: Warttig, S, et al.
Publicado: (2022)

HTA253 Payer Perspectives on the Impact of the COVID-19 Pandemic on Health Technology Assessments (HTA) in Europe
por: Hutcheson, R, et al.
Publicado: (2022)

Evaluation of an Online Version of the CFT 20-R in Third and Fourth Grade Children
por: Visser, Linda, et al.
Publicado: (2022)

Use of Surrogate end points in HTA
por: Mangiapane, Sandra, et al.
Publicado: (2009)

Ethics in HTA: Examining the "Need for Expansion"
por: Abrishami, Payam, et al.
Publicado: (2017)

Impact of COVID-19 pandemic on HTA
Publicado: (2020)

Efficacy of sorafenib in patients with gastrointestinal stromal tumors in the third- or fourth-line treatment: A retrospective multicenter experience
por: KEFELI, UMUT, et al.
Publicado: (2013)

Third-line docetaxel chemotherapy for recurrent and metastatic gastric cancer
por: Lee, Ji Hyun, et al.
Publicado: (2013)

Aneurysmal Subarachnoid Hemorrhage in Third and Fourth Decades of Life
por: Kim, Su-Yong, et al.
Publicado: (2012)

Third, Fourth, and Fifth Annual Accountings, 1913-16
Publicado: (1917)

Cresyl Formothymol in the Treatment of Caries of the Third and Fourth Degree
por: Miegeville, V. E., et al.
Publicado: (1909)

Anthropometric Features and Third-Fourth Degree Perineal Tears
por: Fruscalzo, Arrigo, et al.
Publicado: (2023)

HTA and innovative treatments evaluation: the case of metastatic castration-resistant prostate cancer [Corrigendum]
Publicado: (2019)

Health technology assessment (HTA) and economic evaluation: efficiency or fairness first
por: Richardson, Jeff, et al.
Publicado: (2018)

Fourth-Party Evaluation of Third-Party Pro-social Help and Punishment: An ERP Study
por: Li, Jianbiao, et al.
Publicado: (2018)

Humerus trochlear angle (HTa)—a possible alternative for Baumann angle in the reduction of supracondylar humerus fractures
por: Chen, Gang, et al.
Publicado: (2021)

How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory‐HTA parallel scientific advice
por: Tafuri, Giovanni, et al.
Publicado: (2016)

Using Real-World Data in Health Technology Assessment (HTA) Practice: A Comparative Study of Five HTA Agencies
por: Makady, Amr, et al.
Publicado: (2017)

Towards compatibility of EUnetHTA JCA methodology and German HTA: a systematic comparison and recommendations from an industry perspective
por: Kisser, Agnes, et al.
Publicado: (2021)

International HTA Experience with Targeted Therapy Approvals for Lung Cancer
por: Maraiki, Fatma, et al.
Publicado: (2018)

Design of precise third-line therapy for gastric cancer: target or chemotherpy?
por: Cho, Jae Yong
Publicado: (2013)

Chemorefractory Gastric Cancer: The Evolving Terrain of Third-Line Therapy and Beyond
por: Alsina, Maria, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iaercbffrb9ogtdq11cfn23t60